石药集团在港交所公告称,SYS 6026注射液用于治疗HPV16或18型相关宫颈高级别鳞状上皮内病变的Ⅱ期临床试验在中国正式启动。
石药集团在港交所公告称,SYS 6026注射液用于治疗HPV16或18型相关宫颈高级别鳞状上皮内病变的Ⅱ期临床试验在中国正式启动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.